An interventional study of NEURESCUE device in Cardiac Arrest, Cardiopulmonary Arrest and Cardiovascular Diseases, sponsored by neurescue. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by neurescue · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 107th largest by enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2022, is one of 67 with no phase, and was the 125th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
neurescue is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
neurescue has 4 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.
The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The NEURESCUE device will be used as an adjunct to ACLS.
Device: NEURESCUE device
The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
Successful balloon inflation within 10 minutes from first vessel puncture
Time frame: Assessed up to 10 min
Change in central blood pressure
Time frame: Assessed up to 1 hour
Total ACLS time at initiation of the investigational procedure
Time frame: Assessed up to 1 hour
Time from first vessel puncture to successful sheath insertion
Time frame: Assessed up to 1 hour
Rate of occlusion success
Time frame: Assessed up to 1 hour
Return of spontaneous circulation (ROSC)
The endpoint is dichotomous (yes/no) for each subject
Time frame: Assessed up to 1 hour
Plan to share: No — Individual request
Ran from Dec 2022 to primary completion in Sep 2024, 21 months.
Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
neurescue